Ardelyx Inc
ARDX6.130USD
+0.480+8.50%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.49BMarket Cap
LossP/E TTM
More Details of Ardelyx Inc Company
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Ardelyx Inc Info
Ticker SymbolARDX
Company nameArdelyx Inc
IPO dateJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Number of employees395
Security typeOrdinary Share
Fiscal year-endJun 19
Address400 Fifth Avenue
CityWALTHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02451
Phone15107451700
Websitehttps://www.ardelyx.com/
Ticker SymbolARDX
IPO dateJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Company Executives of Ardelyx Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Mr. James P. Brady
Mr. James P. Brady
Chief Human Resources Officer
Chief Human Resources Officer
166.00K
--
Ms. Sue Hohenleitner
Ms. Sue Hohenleitner
Chief Financial Officer
Chief Financial Officer
146.90K
--
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Mr. James P. Brady
Mr. James P. Brady
Chief Human Resources Officer
Chief Human Resources Officer
166.00K
--
Ms. Sue Hohenleitner
Ms. Sue Hohenleitner
Chief Financial Officer
Chief Financial Officer
146.90K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
IBSRELA
65.05M
0.00%
XPHOZAH
25.03M
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
IBSRELA
65.05M
0.00%
XPHOZAH
25.03M
0.00%
Shareholding Stats
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.54%
BlackRock Institutional Trust Company, N.A.
6.75%
Janus Henderson Investors
6.20%
Macquarie Investment Management
4.72%
Marshall Wace LLP
4.63%
Other
70.17%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.54%
BlackRock Institutional Trust Company, N.A.
6.75%
Janus Henderson Investors
6.20%
Macquarie Investment Management
4.72%
Marshall Wace LLP
4.63%
Other
70.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.73%
Investment Advisor/Hedge Fund
23.68%
Hedge Fund
11.51%
Research Firm
5.24%
Individual Investor
2.92%
Pension Fund
0.38%
Bank and Trust
0.32%
Family Office
0.08%
Private Equity
0.06%
Other
28.08%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
450
167.29M
68.85%
-25.85M
2025Q2
461
180.23M
74.79%
+5.74M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.98M
6.63%
+1.03M
+6.92%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
16.39M
6.8%
+512.18K
+3.23%
Jun 30, 2025
Janus Henderson Investors
15.06M
6.25%
-9.92M
-39.71%
Jun 30, 2025
Macquarie Investment Management
11.46M
4.75%
+299.42K
+2.68%
Jun 30, 2025
Marshall Wace LLP
11.25M
4.67%
+2.87M
+34.19%
Jun 30, 2025
State Street Investment Management (US)
9.84M
4.08%
-334.65K
-3.29%
Jun 30, 2025
Millennium Management LLC
11.66M
4.84%
+5.20M
+80.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.67M
2.35%
-6.52K
-0.11%
Jun 30, 2025
BofA Global Research (US)
4.36M
1.81%
+2.70M
+161.92%
Jun 30, 2025
Nuveen LLC
3.47M
1.44%
+80.04K
+2.36%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.47%
SPDR S&P Biotech ETF
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.42%
Harbor Human Capital Factor US Small Cap ETF
0.39%
Inspire Small/Mid Cap ESG ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Russell 2000 Growth ETF
0.08%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.47%
SPDR S&P Biotech ETF
Proportion0.45%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.42%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.39%
Inspire Small/Mid Cap ESG ETF
Proportion0.26%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.23%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
iShares Russell 2000 Growth ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
